Artiva Biotherapeutics Inc. (ARTV)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA
Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus rituximab in refractory RA. Company's AlloNK plus rituximab demonstrated strong ACR50 response rates in early studies, with phase 3 initiation targeted for 2H 2026 and data expected in 2H 2028. The company addresses a significant unmet need in 3rd-line RA, targeting 150K–200K U.S. patients unresponsive to prior biologics, with a $5 billion spend on this population.
Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored
Artiva Biotherapeutics is working on NK cell-based immunotherapy to treat autoimmune disease. Their lead project is an unmodified, preserved NK product that seeks to address challenges posed for CAR T-cell therapies. Early trial data in B-cell lymphoma suggests activity, and ARTV is guiding a data readout in the near term for autoimmune disease.
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Artiva has two-bagger potential in the eyes of multiple Wall Street analysts. Its cell therapies could provide a much more efficient treatment of autoimmune diseases.
Artiva Biotherapeutics Inc. (ARTV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Artiva Biotherapeutics Inc. ever had a stock split?
Artiva Biotherapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Fred Aslan CEO | NASDAQ (NMS) Exchange | 04317A107 CUSIP |
| US Country | 96 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Artiva Biotherapeutics, Inc. is a trailblazer in the clinical-stage biotechnology arena, with a dedicated focus on developing innovative natural killer (NK) cell-based therapies. These pioneering treatments are designed to offer new hope to patients grappling with a range of autoimmune diseases and cancers. Since its inception in 2019, Artiva has been at the forefront of leveraging cutting-edge science to harness the power of NK cells, propelling forward the fight against some of the most challenging health conditions. Headquartered in the vibrant biotech hub of San Diego, California, Artiva Biotherapeutics is poised to redefine the therapeutic landscape for patients around the globe.
Products and Services
- AB-101:
- AB-201:
- AB-205:
An off-the-shelf NK cell therapy positioned as the company’s lead product candidate. AB-101 is designed to combat a vast array of autoimmune diseases and cancers, providing a beacon of hope for patients with lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, and several subclasses of anti-neutrophil cytoplasmic antibody-associated vasculitis, including granulomatosis with polyangiitis and microscopic polyangiitis. Moreover, it shows promising potential in treating systemic lupus erythematosus and B-cell-non-Hodgkin lymphoma, illustrating Artiva’s commitment to addressing complex health issues with groundbreaking solutions.
An allogeneic anti-human epidermal growth factor receptor 2 (HER2) chimeric antigen receptor (CAR)-NK cell product candidate. AB-201 represents a novel approach in utilizing genetically engineered NK cells to target and eliminate cancer cells expressing HER2, a protein often associated with aggressive forms of cancer. This cutting-edge therapy exemplifies Artiva’s innovative spirit and dedication to pushing the boundaries of cancer treatment.
An allogeneic anti-CD5 CAR-NK cell product candidate, AB-205 stands out as a targeted therapy aiming to harness the power of NK cells against CD5-expressing malignancies. By focusing on this specific therapeutic target, Artiva Biotherapeutics underscores its precision in developing highly specialized treatments intended to improve patient outcomes in the fight against cancer.
